SGCB and stroke disorder: Having established a mechanism-based appearance of apo-sGC upon stroke, we next wanted to examine whether post-stroke pharmacological targeting of apo-sGC by an apo-sGC activator may have the potential of a mechanism-based treatment, i.e. repairing the loss of physiological NO-induced cGMP formation by generating cGMP through apo-sGC.